Indian drug firms cheer dexamethasone efficacy on severe COVID-19 patients

M P Gupta, general manager of Mahima Lifesciences, a Chandigarh-based steroid API maker, said the company was expecting a jump in raw material costs and possible supply disruption if demand goes up.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3fCKQf8
via IFTTT